Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.44 |
| ▸ | ABL1 | P00519 | 12/20 | 0.43 |
| ▸ | BCR | P11274 | 12/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665705 | 0.96 | CYP3A4 (0.44) | HRH3ABL1BCRCYP3A4FGFR3 | |
| SCHEMBL4665832 | 0.93 | MEN1 (0.44) | HRH3ABL1BCRCYP3A4PSEN1 | |
| SCHEMBL4664290 | 0.91 | ABL1 (0.43) | ABL1BCRCYP3A4FGFR3 | |
| SCHEMBL4663885 | 0.90 | FGFR3 (0.41) | HRH3ABL1BCRCYP3A4FGFR3 | |
| SCHEMBL4665779 | 0.88 | CXCR1 (0.47) | ABL1BCRCYP3A4 | |
| SCHEMBL4664370 | 0.88 | ABL1 (0.38) | HRH3ABL1BCRPSEN1PSEN2 | |
| SCHEMBL4666192 | 0.86 | ABL1 (0.42) | ABL1BCR | |
| SCHEMBL4667497 | 0.86 | ABL1 (0.42) | HRH3ABL1BCRCYP3A4 | |
| SCHEMBL4666180 | 0.86 | ABL1 (0.40) | HRH3ABL1BCRCYP3A4 | |
| SCHEMBL4665810 | 0.86 | ABL1 (0.39) | ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | HRH3 887/4885ABL1 24/4885BCR 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.